Strategic Investment to Strengthen AI Capabilities
Veeda Lifesciences, a global contract research organization (CRO), has announced a strategic investment in Mango Sciences, a Boston-based healthcare AI and data company. With this move, Veeda aims to harness cutting-edge artificial intelligence to enhance the speed, efficiency, and quality of its clinical trial services across an expanding global footprint.
By integrating Mango Sciences’ AI-powered Querent™ platform, Veeda plans to streamline patient identification, improve trial design, and expand recruitment capabilities, especially across Europe. This partnership supports more diverse and globally representative patient selection, meeting the rising expectations of both regulators and pharmaceutical clients.
Transforming Oncology Drug Development
“This partnership will transform Veeda into an AI-driven oncology drug development organization,” said Dr. Mahesh Bhalgat, Group CEO and Managing Director of Veeda Clinical Research Limited.
“We are addressing the growing demand for diversity in clinical trials—something increasingly expected by regulatory agencies and pharma companies. With access to Mango’s proprietary technology, we become one of the few CROs specializing in oncology that can offer this capability.”
Driving Digital Transformation in Clinical Research
As per Veeda Lifesciences press release, the collaboration aligns with Veeda’s broader goals of technology modernization and digital transformation. Through the Querent™ platform, the company will automate complex processes, enhance data management, and uphold high-quality standards in its operations. This will enable faster, more accurate patient matching, optimized trial design, and real-time monitoring, ultimately reducing trial timelines and associated costs.
Importantly, the platform also helps ensure better representation of non-Caucasian populations, addressing a longstanding gap in global clinical research.
AI-Powered Insights for Real-World Outcomes
Dr. Mohit Misra, Founder and CEO of Mango Sciences, highlighted the platform’s evolving capabilities:
“We are integrating Large Language Models (LLMs) and Generative AI into Querent™ to further boost operational efficiency and improve real-world evidence. The ultimate goal is to identify the right drug for the right patient, faster and with more accuracy.”
Building a Tech-Enabled, Global CRO
This investment marks another step in Veeda’s mission to become a tech-enabled, AI-driven CRO. Earlier, Veeda had acquired Health Data Specialists (Heads), strengthening its access to valuable oncology patient cohorts in India and Europe. The latest partnership with Mango Sciences gives Veeda exclusive access to highly eligible patient pools, supporting its global clinical research efforts.
Maintaining a Competitive Edge
Through targeted investments in AI and data platforms, Veeda continues to differentiate itself in the CRO sector, delivering advanced, patient-centric services to pharmaceutical and biopharmaceutical clients worldwide. This strategic collaboration further reinforces Veeda’s commitment to innovation, inclusion, and excellence in clinical research.